Your browser doesn't support javascript.
loading
Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis.
Dafni, U; Soo, R A; Peters, S; Tsourti, Z; Zygoura, P; Vervita, K; Han, J-Y; De Castro, J; Coate, L; Früh, M; Hashemi, S M S; Nadal, E; Carcereny, E; Sala, M A; Bernabé, R; Provencio, M; Cuffe, S; Roschitzki-Voser, H; Ruepp, B; Rosell, R; Stahel, R A.
Affiliation
  • Dafni U; National and Kapodistrian University of Athens, Athens, Greece; Frontier Science Foundation Hellas, Athens, Greece.
  • Soo RA; National University Cancer Institute, Department of Haematology-Oncology, Singapore.
  • Peters S; Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Lausanne, Switzerland.
  • Tsourti Z; Frontier Science Foundation Hellas, Athens, Greece.
  • Zygoura P; Frontier Science Foundation Hellas, Athens, Greece.
  • Vervita K; Frontier Science Foundation Hellas, Athens, Greece.
  • Han JY; National Cancer Center, Center for Lung Cancer, Goyang, Republic of Korea.
  • De Castro J; Hospital Universitario La Paz, Medical Oncology Department, Madrid, Spain; Spanish Lung Cancer Group (SLCG), Barcelona, Spain.
  • Coate L; Mid-Western Cancer Centre and University Hospital Limerick, Limerick, Ireland; Cancer Trials Ireland, Innovation House, Dublin, Ireland.
  • Früh M; Cantonal Hospital St. Gallen, Oncology and Hematology, St. Gallen, Switzerland; Inselspital Bern, Department of Oncology, Bern, Switzerland; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland.
  • Hashemi SMS; Amsterdam UMC, VU University Medical Center, Department of Pulmonary Diseases, Amsterdam, the Netherlands.
  • Nadal E; Spanish Lung Cancer Group (SLCG), Barcelona, Spain; ICO L'Hospitalet, Medical Oncology Department, Barcelona, Spain.
  • Carcereny E; Spanish Lung Cancer Group (SLCG), Barcelona, Spain; Institut Català d'Oncologia Badalona-Hospital Germans Trias i Pujol, B-ARGO Group, Medical Oncology Department, Badalona, Spain.
  • Sala MA; Spanish Lung Cancer Group (SLCG), Barcelona, Spain; Hospital Universitario Basurto, Medical Oncology Department, Bilbao, Spain.
  • Bernabé R; Spanish Lung Cancer Group (SLCG), Barcelona, Spain; Hospital Virgen del Rocio, Medical Oncology Department, Seville, Spain.
  • Provencio M; Spanish Lung Cancer Group (SLCG), Barcelona, Spain; Hospital Puerta de Hierro, Majadahonda Medical Oncology Service, Madrid, Spain.
  • Cuffe S; Cancer Trials Ireland, Innovation House, Dublin, Ireland; St. James's Hospital, Department of Medical Oncology, Dublin, Ireland.
  • Roschitzki-Voser H; ETOP IBCSG Partners Foundation, Coordinating Office, Bern, Switzerland.
  • Ruepp B; ETOP IBCSG Partners Foundation, Coordinating Office, Bern, Switzerland.
  • Rosell R; Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain; Catalan Institute of Oncology (ICO), Honorary Consultant, Barcelona, Spain.
  • Stahel RA; ETOP IBCSG Partners Foundation, Coordinating Office, Bern, Switzerland. Electronic address: rolf.stahel@etop.ibcsg.org.
ESMO Open ; 7(3): 100507, 2022 06.
Article in En | MEDLINE | ID: mdl-35696746
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Lung Neoplasms / Antineoplastic Agents Type of study: Clinical_trials / Prognostic_studies / Systematic_reviews Limits: Humans Language: En Journal: ESMO Open Year: 2022 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Lung Neoplasms / Antineoplastic Agents Type of study: Clinical_trials / Prognostic_studies / Systematic_reviews Limits: Humans Language: En Journal: ESMO Open Year: 2022 Document type: Article